Related Experiment Video

Updated: Aug 23, 2025

A Comprehensive Procedure to Evaluate the In Vitro Performance of the Putative Hemangioblastoma Neovascularization Using the Spheroid Sprouting Assay
08:26

A Comprehensive Procedure to Evaluate the In Vitro Performance of the Putative Hemangioblastoma Neovascularization Using the Spheroid Sprouting Assay

Published on: April 12, 2018

8.1K

Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL

Aileen Arevalo1, Neal Patel2,3, Peter Muraki3

  • 1David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

Journal of Kidney Cancer and VHL
|October 31, 2022
PubMed

Insights

Belzutifan

Area of Science:

  • Oncology
  • Genitourinary Cancer
  • Vascular Endothelial Growth Factor Inhibitors

Background:

  • Von Hippel-Lindau (VHL) disease is a genetic disorder associated with increased risk of various cancers, particularly renal cell carcinoma.
  • Recurrent surgical interventions for VHL-associated tumors lead to significant morbidity.
  • Belzutifan, a novel HIF-2α inhibitor, offers a systemic treatment option for VHL disease.

Purpose of the Study:

  • To survey kidney cancer experts in the United States regarding the anticipated utilization of belzutifan for Von Hippel-Lindau disease.
  • To understand expert opinions on treatment indications, initiation, and management strategies with belzutifan.

Main Methods:

  • A survey was developed by the VHL Alliance (VHLA) Clinical Advisory Council.
  • The survey was distributed to kidney cancer providers at VHLA and National Comprehensive Cancer Network (NCCN) centers.
  • Data was collected from 60 respondents (urologists and medical oncologists) across 29 institutions via a secure web-based platform.

Main Results:

  • 98% of experts anticipate belzutifan will significantly alter the VHL treatment landscape.
  • 76% of respondents favor continuous therapy with belzutifan.
  • Significant differences exist in prescribing intent between urologists (38%) and medical oncologists (91%) (P=0.02).

Conclusions:

  • VHL kidney cancer specialists foresee a paradigm shift with belzutifan approval, potentially reducing reliance on surgical management.
  • Expert opinions on initiating belzutifan therapy and managing treatment variations are diverse, highlighting the need for guideline development.
  • Collaborative efforts among experts are crucial for establishing standardized clinical guidelines for belzutifan use in VHL disease.
Keywords:
VHLkidney cancersystemic therapy

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K
Surgical Treatment of an Endolymphatic Sac Tumor04:34

Surgical Treatment of an Endolymphatic Sac Tumor

Published on: May 26, 2023

791

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
18
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
219
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
16
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
235
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25